BIOMERIEUX (BIM.PA) Stock Price, Forecast & Analysis

EPA:BIM • FR0013280286

93.1 EUR
+0.15 (+0.16%)
Last: Feb 12, 2026, 02:53 PM

BIM.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap11.02B
Revenue(TTM)4.12B
Net Income(TTM)378.00M
Shares118.36M
Float43.79M
52 Week High128.3
52 Week Low92.8
Yearly Dividend0.85
Dividend Yield0.92%
EPS(TTM)3.86
PE24.12
Fwd PE18.6
Earnings (Next)03-04
IPO2004-06-07
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
BIM.PA short term performance overview.The bars show the price performance of BIM.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20 -25

BIM.PA long term performance overview.The bars show the price performance of BIM.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -5 -10 -15

The current stock price of BIM.PA is 93.1 EUR. In the past month the price decreased by -14.01%. In the past year, price decreased by -18.82%.

BIOMERIEUX / BIM Daily stock chart

BIM.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
BIM.PA Full Technical Analysis Report

BIM.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to BIM.PA. BIM.PA has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BIM.PA Full Fundamental Analysis Report

BIM.PA Financial Highlights

Over the last trailing twelve months BIM.PA reported a non-GAAP Earnings per Share(EPS) of 3.86. The EPS decreased by -8.45% compared to the year before.


Industry RankSector Rank
PM (TTM) 9.17%
ROA 7.04%
ROE 9.61%
Debt/Equity 0.09
Chartmill High Growth Momentum
EPS Q2Q%-25.82%
Sales Q2Q%7.46%
EPS 1Y (TTM)-8.45%
Revenue 1Y (TTM)8.28%
BIM.PA financials

BIM.PA Forecast & Estimates

17 analysts have analysed BIM.PA and the average price target is 122.03 EUR. This implies a price increase of 31.07% is expected in the next year compared to the current price of 93.1.

For the next year, analysts expect an EPS growth of 15.89% and a revenue growth 5.19% for BIM.PA


Analysts
Analysts75.29
Price Target122.03 (31.07%)
EPS Next Y15.89%
Revenue Next Year5.19%
BIM.PA Analyst EstimatesBIM.PA Analyst Ratings

BIM.PA Ownership

Ownership
Inst Owners21.47%
Ins Owners0.05%
Short Float %N/A
Short RatioN/A
BIM.PA Ownership

BIM.PA Competitors/Peers

The largest stocks on the EU markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
2M6 MEDTRONIC PLC16.14107.599B
SHL SIEMENS HEALTHINEERS AG17.1245.233B
PHIA KONINKLIJKE PHILIPS NV17.7325.662B
PHI1 KONINKLIJKE PHILIPS NV17.4725.595B
DIA DIASORIN SPA18.094.143B
OBCK OTTOBOCK SE & CO KGAA18.763.609B
AFX CARL ZEISS MEDITEC AG - BR11.142.426B
DRW3 DRAEGERWERK AG - PREF11.81.634B
DRW8 DRAEGERWERK AG9.451.294B

About BIM.PA

Company Profile

BIM logo image bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company is headquartered in Craponne, Auvergne-Rhone-Alpes and currently employs 14,754 full-time employees. The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.

Company Info

BIOMERIEUX

376, chemin de l'Orme

Craponne AUVERGNE-RHONE-ALPES FR

Employees: 14451

BIM Company Website

BIM Investor Relations

Phone: 33478872000

BIOMERIEUX / BIM.PA FAQ

What does BIOMERIEUX do?

bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company is headquartered in Craponne, Auvergne-Rhone-Alpes and currently employs 14,754 full-time employees. The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.


What is the stock price of BIOMERIEUX today?

The current stock price of BIM.PA is 93.1 EUR. The price increased by 0.16% in the last trading session.


Does BIM stock pay dividends?

BIOMERIEUX (BIM.PA) has a dividend yield of 0.92%. The yearly dividend amount is currently 0.85.


What is the ChartMill technical and fundamental rating of BIM stock?

BIM.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Is BIOMERIEUX (BIM.PA) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BIM.PA.


Can you provide the number of employees for BIOMERIEUX?

BIOMERIEUX (BIM.PA) currently has 14451 employees.


Can you provide the ownership details for BIM stock?

You can find the ownership structure of BIOMERIEUX (BIM.PA) on the Ownership tab.